1. Introduction
Prostate cancer is the second most common male tumor globally, with 1,276,106 new cases and 358,989 deaths in 2018 [
1,
2]. That is 7.1% of new cases and 3.8% of all male cancer mortality in 2018 [
3]. Globally, the median age for detection of prostate cancer is 66 years old, and both the recurrence and fatality rates rise with age [
4,
5]. Early detection of tumors increases the chances of being cured because treatment works even if the cancer is localized.
Multiparametric magnetic resonance imaging (mp-MRI) has been used extensively in prostate cancer (PCa) scanning, identification, and grading throughout the last few decades [
6,
7]. It is possible to obtain high-resolution anatomical and functional images using the mp-MRI imaging technique [
8]. T
1 weighted images (T
1WI) and T
2 weighted images (T
2WI) are anatomic sequences used in multiparametric prostate MRI. For example, the zonal structure and tumor foci cannot be identified using T
1WI. It is possible to employ T
1WI to discover biopsy-associated haemorrhage, which can interfere with the capacity of other PCa MRI techniques to provide accurate diagnoses. T
2WI provides the best soft-tissue imaging for malignancies, zonal morphology, seminal vesicle (SV), anterior fibromuscular stroma (AFS), neurovascular bundles, and the capsule [
9]. Diffusion-weighted imaging (DWI), Magnetic resonance spectroscopic imaging (MRSI), and Dynamic contrast-enhanced (DCE) are functional MRI sequences [
10]. The DWI technique was developed and implemented to detect an acute cerebrovascular stroke. DWI compares water diffusion in soft tissues and free solution to produce image contrast. When a PCa grows, there is a growth in cellularity and degradation of ductal architecture, which limits fluid flow through the prostate [
11]. The b-value and Apparent Diffusion Coefficient (ADC) are the two types of images used for analysis in DWI. Tumor diagnostic outcome is improved by utilizing b-values between 1,400 and 2,000 [
12,
13,
14]. Clinical interpretation from DWI is subjective; nevertheless, water molecules’ limitations may be measured quantitatively. Interpretation is performed with ADC maps and ADC measurements (mm
2/s). and ADC levels and Gleason scores are proportionally related [
15,
16]. By using a machine learning approach with clinically relevant radiomics metrics as inputs we aim to improve the interpretation and augment clinical diagnosis.
Radiomics improves image analysis by generating (200+) statistical variables from medical images automatically. Patients can significantly vary in shape and texture depending on the imaging technique used [
17] and by utilizing automated or semi-automated radiomics we could improve diagnostic accuracy via statistically analyzing medical images. Textural analysis has been used to extract tissue information from medical images since the 1980s [
18,
19]. It recognizes that intratumor heterogeneity has significant implications for cancer research, which could be represented by tumors’ texture [
20]. Radiomics relies heavily on texture analysis, a necessary part of the process [
21]. Radiomics is the technique used to collect essential and extensive data from clinical images and give variables that can be used to assist in detection, prognostic, and treatment response [
22]. It aids in the classification of benign and malignant tumors and predicts outcomes in practically every tissue [
23,
24,
25,
26,
27]. Furthermore, when developing a radiomics model, selecting the best ML model is significant. Different ML approaches may perform differently when applied to different tissues [
27,
28,
29,
30,
31].
Training is used to derive many of the algorithm parameters used by machine learning, and most contemporary ML algorithms must tune parameters to improve feature identification referred to as
Hyperparameters [
28,
29,
30]. The hyperparameters are fine-tuned to optimize an algorithm for a specific learning task [
32]. Hyperparameter optimization usually employs Grid and Random Search techniques [
33].
Grid Search is a method using all possible permutations of hyperparameters. The training data and the number of layers can be adjusted in a grid search as hyperparameters [
34]. In contrast to a grid search, randomized search does not perform a comprehensive investigation of the hyperparameter space. Nonetheless, it permits us to investigate a wider variety of hyperparameter value settings more effectively and affordably. Weerts et al. [
35] stated that an increased tuning risk and relative tuning risk were observed from the random forest’s max features and SVM’s gamma and C, suggesting that it is essential to tune these hyperparameters. In the domain of prostate cancer classification and grading, many prior studies have applied machine learning techniques with default hyperparameters, often without extensive hyperparameter optimization. In contrast, our research distinguishes itself by prioritizing hyperparameter tuning. This deliberate optimization process enhances the precision and reliability of our machine-learning models, contributing to more accurate and clinically relevant results. Our work aims to advance the field by systematically refining the parameters that underpin the diagnosis of prostate cancer.
The study aimed to use different classifiers (with tuned hyperparameters) and two feature selection methods (i.e., to find the best for classification and prediction). Multiparametric MRI-derived radiomics features were used (including T2WI and ADC map images). First, to quantify tumor heterogeneity between significant versus non-tumor regions. Second, to predict Gleason scores (i.e., G2 = 3 + 4; G3 = 4 + 3; and G4, Gleason primary pattern of 4 + 4 = 8 G4, 3+5 = 8 (G4), 9 (G5) or 10 (G5)) for significant prostate cancer.
4. Discussion
In PCa assessment, mp-MRI has been demonstrated to be a superior technique, allowing for greater accuracy when detecting cancerous growths. That is the only imaging approach with enough spatial resolution and soft tissue contrast to identify prostate cancer effectively [
8] without using ionising radiation. Prostate tumor aggressiveness can be evaluated using artificial intelligence, such as radiomics [
56]. Consequently, radiomics could be an innovative and effective method for extracting further clinically relevant data [
17]. Radiomics can diagnose prostate cancer early, grade it according to Gleason, determine therapy response, and anticipate biochemical recurrence [
56].
Different clinical settings may require different ML techniques for discriminating between sacral chordoma and sacral giant cell malignancies; LASSO using a generalised linear model (GLM) significantly outperformed [
27]. However, when it came to scoring colon microarray gene expression and identifying meningioma, random forest and eXtreme Gradient Boosting (XGBoost) classification methods achieved the best performance [
28,
29,
30,
57]. Wang et al. revealed that the ML approach of recursive elimination features using a support vector machine is better than other feature selection and classification methods [
46]. As a result, it is essential and recommended to discover appropriate machine learning approaches in various clinical implementations in future studies. In the context of prostate cancer classification and grading, our research stands out due to its focus on hyperparameter tuning. While many prior studies have applied machine learning techniques with default hyperparameters, we have systematically optimized these parameters to enhance the precision and robustness of our models. This approach has demonstrated its potential to contribute to more accurate and clinically relevant diagnoses, highlighting the critical role of hyperparameter optimization in medical applications of machine learning.
The Kruskal-Wallis test was utilised to examine radiomics characteristics’ relevance in differentiating significant cancer versus non-tumor regions. Then, Spearman correlation was performed to determine the association between radiomics attributes and significant cancer versus non-tumor regions. Two feature selection methods (REF and LASSO) and two classifiers (RF and SVM) with tuned hyperparameters (randomised search and grid search) were used to create an effective ML algorithm. The analysis between radiomics features and the significant versus non-tumor regions revealed eleven radiomics features that are statistically significant (i.e., skewness, kurtosis, entropylog1o, entropylog2, uniformity, jointEntropyLog2, jointEntropyLog10, correlation, contrast, dissimilarity, and angular second moment) with the capacity to discriminate between the significant and non-tumor regions.
Prostate cancer discrimination employing multiparametric MRI radiomics was designed and tested in this study, and the technique consistently performed well in the present study. As this study reveals, classification accuracy varies between ML techniques. For T
2WI, RF and SVM classifiers were observed to be very useful when used with REF (AUC = 0.95 ± 0.01, and 0.94 ± 0.01, respectively). The second-best result was observed using LASSO selection with SVM and RF classifiers (AUC = 0.93 ± 0.01 for T
2WI, and 0.89 ± 0.00 for ADC map, respectively). That is following previous findings have shown that this system is adequate to other feature selection techniques and classifiers in various organs [
29,
30,
43,
53,
56,
58,
59]. With support vector machines and random forests classifiers, the AUC for the T
2WI sequence was highest with the selection approach using the REF. Radiomic features can be used to identify the T1-2 and T3-4 stages using an unsupervised clustering algorithm and the supervised LASSO technique, according to Sun et al. [
60]. This finding might link to the fact that morphological T
2WI depends on the tumor signal for its assessment. The second-highest AUC was achieved using the selection approach of LASSO with SVM and RF. Wang et al. achieved the best result when combining a support vector machine with recursive feature reduction [
46].
Nevertheless, the T
2WI model performed better than the ADC model (AUCs of 0.95 vs 0.89, respectively). We observed that the AUC of the classification algorithm generated from T
2WI images using RF classifiers using the feature selection technique (RFE) was the highest AUC of 0.95 ± 0.01. In addition, the RFE with the SVM classification algorithm obtained the second maximum AUC of 0.94 ± 0.01 (with 5-fold cross-validation). Additionally, T
2WI could perform a non-invasive analysis of PCa biological growth, which might assist in classifying patients for adequate treatment. It also provides morphologic data for cancer diagnosis, localisation, and staging [
61]. SVM and RF classifiers with LASSO (For LASSO, AUC of 0.89 ± 0.00, 0.89 ± 0.02 for SVM, and RF classifiers, respectively) and RFE (for RFE, AUC of 00.84 ± 0.01, 0.85 ± 0.02 for SVM, and RF classifiers, respectively) for classification between significant cancer versus non-tumor from ADC map images were lower when compared to T
2WI images. For combined sequences (T
2WI and ADC map images), the LASSO with SVM classification algorithms had an AUC of 0.91. The second-highest AUC was 0.88 for the RFE with the RF classification algorithm. Features from several sequences achieved lower performance compared to single sequence features.
The Kruskal-Wallis test assessed radiomics features’ ability to predict GS in prostate cancer patients. Radiomics attributes and GS cohorts were then correlated using Spearman correlation. The ML algorithm was developed using feature selection methods (REF and LASSO) and classifiers (RF and SVM) with tuned hyperparameters (randomised search and grid search). ADC map images revealed one radiomics feature from the uniformity that could distinguish GS cohorts.
For combined sequences (T2WI and ADC map images), the LASSO with RF classification algorithm obtained the highest AUC of 0.92 to predict G3 compared to G4 (SVM-LASSO, AUC = 0,78) and G2 (RF-LASSO, AUC = 0.66). In addition, for T2WI images, using GLCM features, the LASSO with SVM classification algorithm obtained the highest AUC of 0.92 to predict G3 compared to G2 (RF-LASSO, AUC = 0,56) and G4 (SVM-LASSO, AUC = 0.61). Furthermore, for ADC map images, using the 1st order features, the LASSO with RF classification algorithm obtained the highest AUC of 0.82 to predict G2 compared to G3 (SVM-RFE, AUC = 0,81) and G4 (SVM-LASSO, AUC = 0.53). Additionally, for T2WI images, using First-order features, the LASSO with RF classification algorithm obtained the highest AUC of 0.81 to predict G4 compared to G2 (SVM-LASSO and RF-RFE, AUC = 0,66, and 0.66 respectively) and G4 (RF-RFE, AUC = 0.78).
The results we obtained agree with those of several other studies using texture analysis. It was shown that GLCM texture features are helpful for both PCa detection and GS evaluation [
62,
63]. Texture features, such as those of the first and second order derived from ADC and T
2WI, and sample augmentation, were demonstrated to effectively achieve reasonably accurate classification of Gleason patterns [
53]. Our findings align with employing the Gleason score as the primary criterion for differentiating benign from significant prostate tumors.
There were a few limitations identified in this research. As a starting point, we included only 71 patients and additional validation of these findings in a more significant subject cohort is required. Moreover, validation in multiple clinical settings is required to obtain high-level confirmation for its medical use. We agree that there are limitations to this work and that in clinical settings there are compromises made on mismatched resolutions. Ideally all our data and all clinical data would be at the same resolution field strength etc. providing uniformity in data acquisition and this step could be avoided. Due to the nature of clinical MRI time and the time requirement of different sequences employed this mismatch of resolutions will persist for the near future…
5. Conclusion
Within the scope of this study, the classification of prostate cancer and prediction of GS groups using multiparametric MRI-based radiomics has been proposed. This study presents two types of feature selection and two classifier algorithms with tuning hyperparameters. Our study presents a distinct approach to the classification and grading of prostate cancer. By prioritizing hyperparameter tuning, we have significantly improved the precision and reliability of our machine-learning models. This work underscores the importance of meticulous parameter optimization in enhancing the accuracy of medical diagnoses.
Radiomics analysis based on multiparametric MRI showed excellent results in discriminating non-tumor regions from significant prostate cancer results obtained. Findings suggest that recursive feature elimination as a feature selection method with SVM and RF is the best method for classifying significant cancer from non-tumor regions. The second approach we found for classification is LASSO, which combines feature selection methods with SVM and RF. Compared to features taken from a single sequence, the performance of features taken from multiple sequences was lower.
The results of the radiomics analysis, which depended on the multiparametric MRI, demonstrated superior outcomes in predicting between GS groups. This study used combined sequences (ADC and T2WI) and radiomics features to classify three groups of GS utilising RF and SVM classifiers with tuned parameters. When combining sequences (T2WI and ADC map images) and radiomics features (1st and GLCM), LASSO with RF had the highest AUC of 0.92, which enabled it to predict G3. When GLCM features were used, LASSO with SVM achieved the highest AUC (0.92 to predict G3) for single sequence analysis (T2WI images).
Our approach suggests that using multiple features and classifiers with tuning hyperparameters provided a more clinically dependable method of identifying clinically relevant features. It is essential to perform additional prospective studies to verify and establish the significance of our findings.
Figure 1.
Patient exclusion criteria flowchart.
Figure 1.
Patient exclusion criteria flowchart.
Figure 2.
The prostate cancer classification scheme includes: (i) using ROIs that matched where the cancer was on the histology slides and MRI (T2 weighted images and Apparent Diffusion Coefficient map images of 71 subjects with confined histology and magnetic resonance imaging prostate cancer made); (ii) features extraction, including 1st and 2nd orders; (iii) ROC-AUC analysis, including ROC curves.
Figure 2.
The prostate cancer classification scheme includes: (i) using ROIs that matched where the cancer was on the histology slides and MRI (T2 weighted images and Apparent Diffusion Coefficient map images of 71 subjects with confined histology and magnetic resonance imaging prostate cancer made); (ii) features extraction, including 1st and 2nd orders; (iii) ROC-AUC analysis, including ROC curves.
Figure 3.
The classification of prostate cancer as significant versus non-tumor regions depends on RFE using mp-MRI within a 5-fold cross-validation.
Figure 3.
The classification of prostate cancer as significant versus non-tumor regions depends on RFE using mp-MRI within a 5-fold cross-validation.
Figure 4.
The classification of prostate cancer as significant versus non-tumor regions depends on LASSO using mp-MRI within a 5-fold cross-validation.
Figure 4.
The classification of prostate cancer as significant versus non-tumor regions depends on LASSO using mp-MRI within a 5-fold cross-validation.
Figure 5.
The classification of prostate cancer as significant versus non-tumor regions depends on RFE using mp-MRI within a 5-fold cross-validation.
Figure 5.
The classification of prostate cancer as significant versus non-tumor regions depends on RFE using mp-MRI within a 5-fold cross-validation.
Figure 6.
The classification of prostate cancer as significant versus non-tumor regions depends on LASSO using mp-MRI within a 5-fold cross-validation.
Figure 6.
The classification of prostate cancer as significant versus non-tumor regions depends on LASSO using mp-MRI within a 5-fold cross-validation.
Figure 7.
Accuracy of non-tumor regions and significant tumor discrimination of prostate cancer in the test set.
Figure 7.
Accuracy of non-tumor regions and significant tumor discrimination of prostate cancer in the test set.
Figure 8.
Accuracy of non-tumor regions and significant tumor discrimination of prostate cancer in the training set.
Figure 8.
Accuracy of non-tumor regions and significant tumor discrimination of prostate cancer in the training set.
Figure 9.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using 1st order features and GLCM features obtained from T2WI and ADC map images.
Figure 9.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using 1st order features and GLCM features obtained from T2WI and ADC map images.
Figure 10.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using 1st-order features obtained from ADC map images.
Figure 10.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using 1st-order features obtained from ADC map images.
Figure 11.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using GLCM features obtained from ADC map images.
Figure 11.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using GLCM features obtained from ADC map images.
Figure 12.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using 1st-order features obtained from T2WI images.
Figure 12.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using 1st-order features obtained from T2WI images.
Figure 13.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using GLCM features obtained from T2WI images.
Figure 13.
ROC-AUC of predicting Gleason Score of PCa from RF and SVM classifiers (using RFE and LASSO feature selections) using GLCM features obtained from T2WI images.
Table 1.
Multiparametric MRI sequence parameters.
Table 1.
Multiparametric MRI sequence parameters.
Sequence parameter |
T2WI |
ADC |
Repetition time (ms) |
5560 |
2700 |
Echo time (ms) |
104 |
63 |
Flip angle (degrees) |
160 |
90 |
Bandwidth (Hz/px) |
200 |
1500 |
Phase FoV % |
100 |
65.625 |
Slice thickness (mm) |
3 |
3 |
Slice gap (mm) |
3 |
3 |
Average |
4 |
8 |
Phase encoding direction |
Row |
Row |
Number of acquisitions |
1 |
1 |
Table 2.
Comparisons of radiomics parameters of significant cancer versus non-tumor regions.
Table 2.
Comparisons of radiomics parameters of significant cancer versus non-tumor regions.
Feature |
Median (interquartile 25th,50th, and 75th percentiles) |
P |
Significant cancer |
nontumor regions |
ADC |
|
|
|
1st order |
|
|
|
Skewness |
0.37 (0.02, 0.37, 0.69) |
0.03 (-0.29, 0.03, 0.47) |
0.001 |
Kurtosis |
-0.49 (-0.85, -0.49, 0.29) |
-0.54 (-0.86, -0.54, -0.12) |
0.52 |
Entropylog1o |
1.14 (1.09, 1.14, 1.19) |
1.09 (1.05, 1.09, 1.14) |
˂ 0.001 |
Entropylog2 |
3.80 (3.62, 3.80, 3.97) |
3.62 (3.50, 3.62, 3.80) |
˂ 0.001 |
Uniformity |
0.07 (0.06, 0.07, 0.08) |
0.08 (0.07, 0.08, 0.10) |
˂ 0.001 |
GLCM |
|
|
|
JointEntropyLog2 |
6.18 (5.85, 6.18, 6.45) |
6.05(5.83,6.05,6.21) |
0.03 |
JointEntropyLog10 |
1.86 (1.79, 1.86, 1.94) |
1.82(1.75,1.82,1.87) |
0.006 |
Angular Second Moment |
0.01 (0.01, 0.1, 0.01) |
0.016 (0.014, 0.016, 0.019) |
0.006 |
Contrast |
145.64 (107.88, 145.64, 201.96) |
84.02 (59.85, 84.02, 122.08) |
˂ 0.001 |
Dissimilarity |
9.30 (8.33, 930, 11.36) |
7.51 (6.19, 7.51, 8.61) |
˂ 0.001 |
Correlation |
0.18 (0.06, 0.18, 0.35) |
0.23 (0.09, 0.23, 0.39) |
0.37 |
T2WI |
|
|
|
1st order |
|
|
|
Skewness |
0.07 (-0.20, 0.07, 0.32) |
0.15 (-0.20, 0.15, 0.43) |
0.50 |
Kurtosis |
-0.18 (-0.55, -0.018, 0.43) |
-0.34 (-0.59, -0.34, 0.11) |
0.18 |
Entropylog1o |
1.30 (1.23, 1.30, 1.41) |
1.06 (0.97, 1.06, 1.16) |
˂ 0.001 |
Entropylog2 |
4.34 (4.11, 4.34, 4.69) |
3.52 (3.24, 3.52, 3.85) |
˂ 0.001 |
Uniformity |
0.05 (0.04, 0.05, 0.06) |
0.09 (0.07, 0.09, 0.12) |
˂ 0.001 |
GLCM |
|
|
|
JointEntropyLog2 |
7.50 (6.89, 7.50, 8.16) |
6.45 (5.95,6.45,7.12) |
˂0.001 |
JointEntropyLog10 |
2.31 (2.12, 2.31, 2.50) |
1.96 (1.79,1.96,2.14) |
˂ 0.001 |
Angular Second Moment |
0.006 (0.004, 0.006, 0.01) |
0.01 (0.01, 0.01, 0.02) |
˂ 0.001 |
Contrast |
92.42 (64.22, 92.42, 132.48) |
13.36 (10.08, 13.36, 20.47) |
˂ 0.001 |
Dissimilarity |
7.62 (6.36, 7.62, 9.07) |
2.88 (2.46, 2.88, 3.60) |
˂ 0.001 |
Correlation |
0.25 (0.13, 0.25, 0.35) |
0.38 (0.24, 0.38, 0.50) |
˂ 0.001 |
Table 3.
Features associated with the significant malignancy and the non-tumor regions are considered correlated.
Table 3.
Features associated with the significant malignancy and the non-tumor regions are considered correlated.
Feature |
r |
P |
ADC |
|
|
1st order |
|
|
Skewness |
0.315 |
˂0.001 |
Entropylog1o |
0.305 |
˂0.001 |
Entropylog2 |
0.305 |
˂0.001 |
Uniformity |
-0.331 |
˂0.001 |
GLCM |
|
|
Angular Second Moment |
-0.236 |
0.005 |
Contrast |
0.376 |
˂0.001 |
Dissimilarity |
0.468 |
˂0.001 |
T2WI |
|
|
1st order |
|
|
Entropylog1o |
0.561 |
˂0.001 |
Entropylog2 |
0.561 |
˂0.001 |
Uniformity |
-0.254 |
0.002 |
GLCM |
|
|
JointEntropyLog2 |
0.270 |
0.001 |
JointEntropyLog10 |
0.269 |
0.001 |
Contrast |
0.765 |
˂0.001 |
Dissimilarity |
0.809 |
˂0.001 |
Correlation |
0.370 |
˂0.001 |
Table 4.
Comparisons of radiomics parameters of prostate cancer that are associated with the Gleason score groupings.
Table 4.
Comparisons of radiomics parameters of prostate cancer that are associated with the Gleason score groupings.
Feature |
Gleason Score Median (interquartile 25th,50th, and 75th percentiles) |
P |
G2 |
G3 |
G4 |
ADC |
|
|
|
|
1st order |
|
|
|
|
Skewness |
0.30 (-0.01, 0.30, 0.58) |
0.60 (-0.12, 0.60, 1.24) |
0.39 (0.10, 0.39, 0.75) |
0.92 |
Kurtosis |
-0.49 (-0.87, -0.49, 0.26) |
-0.38 (-0.78, -0.38, 1.24) |
-0.34 (-0.90, -0.34, 0.49) |
0.81 |
Entropylog1o |
1.12 (1.08, 1.12, 1.16) |
1.15 (1.09, 1.15, 1.21) |
1.16 (1.09, 1.16, 1.22) |
0.03 |
Entropylog2 |
3.75(3.61, 3.75, 3.87) |
3.83 (3.62, 3.83, 4.03) |
3.88 (3.64, 3.88, 3.06) |
0.03 |
Uniformity |
0.07(0.07, 0.07, 0.08) |
0.07 (0.06, 0.07, 0.08) |
0.07 (0.06, 0.07, 0.08) |
0.01 |
GLCM |
|
|
|
|
JointEntropyLog2 |
6.12 (5.87, 6.12, 6.47) |
7.84 (7.42, 7.84, 8.22) |
6.28 (6.11, 6.28, 6.60) |
0.03 |
JointEntropyLog10 |
1.84 (1.76, 1.84, 1.94) |
2.36 (2.24, 2.36, 2.54) |
1.89 (1.83, 1.89, 1.98) |
0.18 |
Angular Second Moment |
0.02 (0.01, 0.02, 0.02) |
0.005(0.0037, 0.005, 0.006) |
0.01 (0.01, 0.01, 0.01) |
0.05 |
Contrast |
132.43 (101.12, 132.43, 182.76) |
83.79 (64.25, 83.79, 128.98) |
149.88 (107.82, 149.88, 220.89) |
0.15 |
Dissimilarity |
9.01 (8.05, 9.01, 10.79) |
7.09 (6.25, 7.09, 9.03) |
9.84 (8.25, 9.84, 11.96) |
0.14 |
Correlation |
0.18 (0.02, 0.18, 0.33) |
0.26 (0.14, 0.26, 0.47) |
0.20 (0.05, 0.20, 0.41) |
0.54 |
T2WI |
|
|
|
|
1st order |
|
|
|
|
Skewness |
0.03 (-0.22, 0.03, 0.29) |
0.23 (-0.12, 0.23, 0.47) |
-0.03 (-0.26, -0.03, 0.23) |
0.85 |
Kurtosis |
-0.14 (-0.47, -0.14, 0.64) |
0.07 (-0.39, 0.07, 0.27) |
-0.62 (-0.76, -0.62, -0.31) |
0.78 |
Entropylog1o |
1.29 (1.23, 1.29, 1.38) |
1.33 (1.26, 1.33, 1.44) |
1.28 (1.18, 1.28, 1.38) |
0.76 |
Entropylog2 |
4.31 (4.09, 4.31, 4.61) |
4.42 (4.20, 4.42, 4.47) |
4.28 (3.92, 4.28, 4.61) |
0.76 |
Uniformity |
0.05 (0.04, 0.05, 0.06) |
0.05 (0.04, 0.05, 0.06) |
0.05 (0.04, 0.05, 0.07) |
0.80 |
GLCM |
|
|
|
|
JointEntropyLog2 |
7.48 (6.87, 7.48, 8.16) |
6.17 (5.75, 6.17, 6.41) |
7.12 (6.79, 7.12, 8.23) |
0.40 |
JointEntropyLog10 |
2.28 (2.11, 2.28, 2.25) |
1.88 (1.76, 1.88, 2.01) |
2.19 (2.06, 2.19, 2.48) |
0.72 |
Angular Second Moment |
0.008 (0.004, 0.01, 0.01) |
0.01(0.01, 0.01, 0.02) |
0.01(0.01, 001, 0.01) |
0.69 |
Contrast |
94.93 (69.61, 94.93, 138.60) |
180.96 (126.01, 180.96, 280.64) |
101.25 (54.24, 101.25, 125.81) |
0.62 |
Dissimilarity |
7.68 (6.58, 7.68, 9.03) |
9.71 (8.62, 9.71, 13.23) |
7.97 (6.06, 7.97, 9.17) |
0.63 |
Correlation |
0.24 (0.10, 0.24, 0.34) |
0.24 (0.07, 0.24, 0.33) |
0.22 (0.14, 0.22, 0.31) |
0.78 |
Table 5.
Features that are associated with the Gleason score groupings regions are considered correlates.
Table 5.
Features that are associated with the Gleason score groupings regions are considered correlates.
Feature |
r |
P |
ADC |
|
|
1st order |
|
|
Uniformity |
-0.30 |
0.02 |